Meghana Keshavan

Meghana Keshavan

Meghana has spent the last year-and-a-half writing about biotech and healthcare for the San Diego Business Journal. Previously, she's worked for Reuters, Crain’s Detroit Business, the Detroit Free Press and WDET, a Detroit-based National Public Radio affiliate. Meghana studied biochemistry and molecular biology at Penn State University and spent five years as a self-described "research peon in a schizophrenia genetics lab."

Follow Meghana Keshavan: Twitter |


Cloud computing: A critical component of precision medicine

Cloud computing: A critical component of precision medicine

January 23, 2015 6:00 am by | 0 Comments

Phenotyping needs to catch up with genotyping: That’s one key move that must be made for us to bring this precision medicine thing to widespread fruition. And to connect these…


Regenxbio nets $30M to bring its gene therapy to clinical trial

Regenxbio nets $30M to bring its gene therapy to clinical trial

January 22, 2015 5:52 am by | 0 Comments

Washington, D.C.-based gene therapy outfit Regenxbio just raised $30 million to bring its platform into the clinic. The dollars will help Regenxbio generate clinical proof of concept data, as well as work toward…



IRX Therapeutics raises $31.6M to start Phase 2B trials of its ‘generic’ immunity-boosting cancer drug

IRX Therapeutics raises $31.6M to start Phase 2B trials of its ‘generic’ immunity-boosting cancer drug

January 20, 2015 2:38 pm by | 1 Comments

New York biotech IRX Therapeutics just raised $31.6 million to finance later stage trials of its fast-tracked immunity-boosting cancer therapeutic, IRX-2. The randomized head and neck cancer Phase 2B trial will…


Whistleblower suit against billionaire Soon-Shiong’s startup, NantHealth, calls its practices “fraudulent”

Whistleblower suit against billionaire Soon-Shiong’s startup, NantHealth, calls its practices “fraudulent”

January 16, 2015 2:31 pm by | 1 Comments

Billionaire surgeon Patrick Soon-Shiong has developed quite the high profile – regarded as a kind of Tony Stark of health care. His hush-hush startup, NantHealth, has attracted hundreds of millions in…


PwC Report: Biotech venture investment killed it in 2014 with $6B raised

PwC Report: Biotech venture investment killed it in 2014 with $6B raised

January 16, 2015 6:00 am by | 1 Comments

Biotech was one of the top sectors in the country to receive venture capital investment, according to a new report from PricewaterhouseCoopers. Two of 2014’s top venture capital investments were…


NeuroPhage adds $10M to its Series D to bring brain plaque-clearing Alzheimer’s drug to clinic

NeuroPhage adds $10M to its Series D to bring brain plaque-clearing Alzheimer’s drug to clinic

January 16, 2015 5:30 am by | 0 Comments

Cambridge-based NeuroPhage is developing, well, a better way to clear the trash. It’s chasing Alzheimer’s, Parkinson’s and other aging-related degenerative diseases with a technology that breaks up disease-causing plaques in the brain. The company…


Just a cool #JPM15 Bluebird Bio slide that shows its impressive scope

Just a cool #JPM15 Bluebird Bio slide that shows its impressive scope

January 15, 2015 1:50 pm by | 0 Comments

Bluebird Bio‘s work has been at the epicenter of gene therapy, working on a litany of fields that intersect with the work of the industry’s top firms. This slide from its J.P….



The kinds of startups Canaan Partners is looking to invest in

The kinds of startups Canaan Partners is looking to invest in

January 14, 2015 9:36 pm by | 0 Comments

Hey, startups: I chatted this week at the J.P. Morgan conference with Brent Ahrens of Canaan Partners about the venture firm’s recent $675 million fund – it’s tenth and largest – and…


#JPM15: Ezekiel Emanuel talks health care costs – and why many cancer drugs just aren’t worth it

#JPM15: Ezekiel Emanuel talks health care costs – and why many cancer drugs just aren’t worth it

January 13, 2015 9:55 pm by | 5 Comments

Ezekiel Emanuel didn’t talk death-at-75 at this week’s J.P. Morgan conference – he talked money. Namely, the costs associated with health care – what counts as appropriate expenditure, and what’s…


#JPM15: Bristol-Myers Squibb bullish on immuno-oncology, but what of the patent expiries?

#JPM15: Bristol-Myers Squibb bullish on immuno-oncology, but what of the patent expiries?

January 13, 2015 12:57 pm by | 1 Comments

Despite the influx of recent, positive news from Bristol-Myers Squibb, CEO Lamberto Andreotti remained a bit cagey during today’s JP Morgan presentation about the company’s plan this year to recover from major…


The future of next-gen sequencing (and why an Illumina cofounder’s never had his genome mapped)

The future of next-gen sequencing (and why an Illumina cofounder’s never had his genome mapped)

January 13, 2015 5:30 am by | 0 Comments

John Stuelpnagel – one of Illumina‘s cofounders – has never had his genome sequenced. “I didn’t feel the need,” Stuelpnagel said. It’s not because of the cost, nor the fear…


#JPM15: Merck CEO on key areas of focus – and potential acquisition

#JPM15: Merck CEO on key areas of focus – and potential acquisition

January 13, 2015 5:00 am by | 0 Comments

Merck will follow big pharma’s standard MO of looking elsewhere to bring new assets in-house, CEO Kenneth Frazier said at this week’s J.P. Morgan healthcare investing conference. “As we move into 2015,…


#JPM15 Buzz: BIG deals, and a bobblehead

#JPM15 Buzz: BIG deals, and a bobblehead

January 12, 2015 3:29 am by | 0 Comments

The eve of JP Morgan healthcare investment conference’s launch was marked by binge drinking, a number of big deals – and the bobblehead doppelgänger of TheStreet’s Adam Feuerstein, who shant be at…


Poltroons and pick-up lines: What’s buzzing at #JPM15

Poltroons and pick-up lines: What’s buzzing at #JPM15

January 11, 2015 1:41 pm by | 2 Comments

Happy JP MorganWeek! Presenting companies have been bottling up the best news they can muster, to announce with aplomb this week at the premier biotech investing event in the country. It’s already begun: Shire…


Irish VC Fountain Healthcare launches $127.5M fund

Irish VC Fountain Healthcare launches $127.5M fund

January 9, 2015 1:46 pm by | 0 Comments

Fountain Healthcare Partners just closed its second fund, with €85 million – or about $127.5 million. The Irish VC firm – which has offices in New York – plans to make…